Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06953869

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
420 (estimated)
Sponsor
Vanda Pharmaceuticals · Industry
Sex
All
Age
2 Years – 17 Years
Healthy volunteers
Not accepted

Summary

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.

Conditions

Interventions

TypeNameDescription
DRUGTasimelteon Oral SuspensionSingle daily dose, weight-based liquid suspension formulation.
DRUGPlaceboPlacebo comparator.

Timeline

Start date
2025-04-21
Primary completion
2027-11-01
Completion
2028-01-01
First posted
2025-05-01
Last updated
2025-05-01

Locations

3 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06953869. Inclusion in this directory is not an endorsement.